Efficacy of ursodeoxycholic acid in combination with interferon-α in treating chronic hepatitis C: Results of a long-term follow-up trial

Journal of Gastroenterology and Hepatology (Australia)

Volumn 11, Issue 12, 1996, Pages 1155-1160

  Tanaka, Katsuaki ^a   Kondo, Masaaki ^a   Sakaguchi, Takashi ^a   Saito, Satoru ^a   Arata, Shinju ^a   Ikeda, Masanori ^a   Kitamura, Takehiko ^a   Morimoto, Manabu ^a   Sekihara, Hisahiko ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

chronic hepatitis C; HCV RNA; interferon; ursodeoxycholic acid

Indexed keywords

ALPHA INTERFERON; RECOMBINANT ALPHA2A INTERFERON; URSODEOXYCHOLIC ACID;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; TREATMENT OUTCOME;

EID: 0030482377     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1996.tb01844.x     Document Type: Article

References (36)

1. Kuo G, Choo QL, Alter HJ et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244: 362-4.
2. Kiyosawa K, Sodeyama T, Tanaka E et al. Inter-relationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12: 671-5.
3. Dienstag JL. Non-A, non-B hepatitis. I. Recognition, epidemiology, and clinical features. Gastroenterology 1983; 85: 439-62.
4. Hoofnagle JH, Mullen KD, Jones DB et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: A preliminary report. N. Engl. J. Med. 1986; 315: 1575-8.
5. Davis GL, Balart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon alpha: A multicenter randomized, controlled trial. N. Engl. J. Med. 1989; 321: 1501-6.
6. Di Bisceglie AM, Martin P, Kassianides C et al. Recombinant interferon alpha therapy for chronic hepatitis C: A randomized, double-blind, placebo-controlled trial. N. Engl. J. Med. 1989; 321: 1506-10.
7. Tine F, Margin S, Craxi A, Pagliaro L. Interferon for non-A, non-B chronic hepatitis: A meta-analysis of randomized clinical trials. J. Hepatol. 1991; 13: 192-9.
8. Marcellin P, Boyer N, Giostra E et al. Recombinant human α-interferon in patients with chronic non-A, non-B hepatitis: A multicenter randomized controlled trial from France. Hepatology 1991; 13: 393-7.
9. Poupon RE, Balkau B, Eschwege E, Poupon R, the UDCA-PBC Study Group. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N. Engl. J. Med. 1991; 324: 1548-54.
10. Crosignani A, Battezzati PM, Setchell KDR et al. Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis: A dose-response study. Hepatology 1991; 13: 339-44.
11. De Caestecker JS, Jazrawi RP, Petroni ML, Northfield TC. Ursodeoxycholic acid in chronic liver disease. Dig. Dis. Sci. 1991; 36: 1061-5.
12. Guslandi M. Treatment of chronic liver disease with ursodeoxycholic acid. J. Int. Med. Res. 1990; 18: 497-505.
13. Podda M, Ghezzi C, Battezzati PM et al. Effect of different doses of ursodeoxycholic acid in chronic liver disease. Dig. Dis. Sci. 1989; 34 (Suppl.): S59-65.
14. Rolandi E, Franceschini R, Cataldi A, Cicchetti V, Carati L, Barreca T. Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis. A double-blind controlled study. Eur. J. Clin. Pharmacol. 1991; 40: 473-6.
15. Bellentani S, Podda M, Tiribelli C et al. Ursodiol in the long-term treatment of chronic hepatitis: A double-blind multicenter clinical trial. J. Hepatol. 1993; 19: 459-64.
16. Angelico M, Gandin C, Pescarmona E et al. Recombinant interferon-α and ursodeoxycholic acid versus interferon-α alone in the treatment of chronic hepatitis C: A randomized clinical trial with long-term follow-up. Am. J. Gastroenterol. 1995; 90: 263-9.
17. Boucher E, Jouanolle H, Andre P et al. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: Results from a controlled randomized trial in 80 patients. Hepatology 1995; 21: 322-7.
18. Chomczynski P, Sacchi N. Single-step RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 1987; 162: 156-9.
19. Saiki RK, Walsh PS, Levenson CH, Erlich HA. Genetic analysis of amplified DNA with immobilized sequence-specific oligonucleotide probes. Proc. Natl Acad. Sci. USA 1989; 86: 6230-4.
20. Gunji T, Kato N, Hijikata M, Hayashi K, Saitoh S, Shimotohno K. Specific detection of positive and negative stranded hepatitis C viral RNA using chemical RNA modification. Arch. Virol. 1994; 134: 293-302.
21. Kwok S, Higuchi R. Avoiding false positives with PCR. Nature 1989; 339: 237-8.
22. Gilliland G, Perrin S, Blanchard K, Bunn HF. Analysis of cytokine mRNA and DNA: Detection and quantitation by competitive polymerase chain reaction. Proc. Natl Acad. Sci. USA 1990; 87: 2725-9.
23. Okamoto H, Sugiyama Y, Okada S et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infections sources. J. Gen. Virol. 1992; 73: 673-9.
24. Guldutuna S, Zummer G, Imhof M, Bhatti S, You T, Leuschner U. Molecular aspects of membrane stabilisation by ursodeoxycholate. Gastroenterology 1993; 104: 1736-44.
25. Scholmerich J, Becher MS, Schmidt K et al. Influence of hydroxylation and conjugation of bile salts on their membrane damaging properties: Studies on isolated hepatocytes and lipid membrane vesicles. Hepatology 1984; 4: 661-6.
26. Heuman DM, Mills AS, McCall J, Hylemon PB, Pandak WM, Vlahcevic ZR. Conjugates of ursodeoxycholate protect against cholestasis and hepatocellular necrosis caused by more hydrophobic bile salts. In vivo studies in the rat. Gastroenterology 1991; 100: 203-11.
27. Hagiwara H, Hayashi N, Mita E et al. Quantitative analysis of hepatitis C virus RNA in serum during interferon alpha therapy. Gastroenterology 1993; 104: 877-83.
28. Gil B, Quian C, Riezu-Boj JI, Civeira MP, Prieto J. Hepatic and extrahepatic HCV-RNA strands in chronic hepatitis C: Different patterns of response to IFN treatment. Hepatology 1993; 18: 1050-4.
29. Beach MJ, Meeks EL, Mimms LT et al. Temporal relationships of hepatitis C virus RNA and antibody responses following experimental infection of chimpanzees. J. Med. Virol. 1992; 36: 226-37.
30. Lau JYN, Davis GL, Kniffen J et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993; 341: 1501-4.
31. Ward A, Broyden RN, Heel RC et al. Ursodeoxycholic acid: Review of its pharmacological properties and therapeutic efficacy. Drugs 1984; 27: 95-131.
32. Calmus Y, Gane P, Rouger P, Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: Effect of ursodeoxycholic acid. Hepatology 1990; 11: 12-15.
33. Hillaire H, Boucher E, Calmus Y et al. Bile acids modulate hepatocyte HLA class I expression in human hepatocytes by a transcriptional mechanism. Gastroenterology 1994; 107: 781-8.
34. Onji M, Kikuchi T, Kumon I et al. Intrahepatic lymphocyte subpopulations and HLA class I antigen expression by hepatocytes in chronic hepatitis C. Hepatogastroenterology 1992; 39: 340-3.
35. Negro F, Pacchioni D, Shimizu Y. Detection of intrahepatic replication of hepatitis C virus RNA by in situ hybridization and comparison with histopathology. Proc. Natl Acad. Sci. USA 1992; 89: 2247-51.
36. Takano S, Ito Y, Yokosuka O et al. A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology 1994; 20: 558-64.